Responses
Clinical and epidemiological research
Extended report
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
Compose a Response to This Article
Other responses
No responses have been published for this article.